Patient Summary: Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831

Carolyn Vachani, RN, MSN, AOCN
Abramson Cancer Center of the University of Pennsylvania
Last Modified: June 9, 2006

Share article


Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831

NCCTG N9831 is a 3-arm randomized Phase III trial involving stage I-IIA breast cancer patients comparing the safety and efficacy of doxorubicin / cyclophosphamide (AC) followed by weekly paclitaxel vs the same chemotherapy with 1 yr of trastuzumab given either concurrently with paclitaxel or started after paclitaxel. Interim results of this trial have been previously reported. This report focused on the safety of administering radiation therapy in conjunction with trastuzumab, given its known cardiac toxicity and the close proximity of radiation to the heart.

The number of cardiac events was low in all three arms, with or without radiation therapy (0.7% without trastuzumab, 5.2% in the sequential trastuzumab arm, and 7.5% in the concurrent trastuzumab arm). Radiation (RT) did not increase the number of cardiac events in the groups receiving trastuzumab (2.5% with RT vs. 2.7% without RT in the sequential arm, 1.7% with RT vs. 5.8% without RT in the concurrent arm).

The main point of this abstract is that radiation therapy given concurrently with trastuzumab appears safe from a cardiac standpoint. This conclusion is limited by the fact that there is a relatively short amount of patient follow-up in this study (median follow-up 1.5 years). Radiation therapy is known to cause late appearing toxicities, and cardiac damage from radiation could manifest as far out as 10-15 years following treatment. Thus it seems somewhat premature to conclude that trastuzumab given concurrently with radiation is completely safe. When this data has matured, we will have a better idea as to the benefits and risks of these combination regimens.


News
SEER Data Under-Ascertaining Cancer Radiotherapy Rates

Jul 12, 2011 - Data from the Surveillance, Epidemiology, and End Results registry show disparities in documenting rates of radiotherapy receipt by breast cancer patients or for investigation of geographic variation in the radiation treatment, according to a study published online June 29 in Cancer.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More